Edgewise Therapeutics, Inc. EWTX Business Segments — Allocated Share Based Compensation Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Edgewise Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.
The official record: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Edgewise Therapeutics, Inc.'s business segments — allocated share based compensation expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Edgewise Therapeutics, Inc.'s business segments — allocated share based compensation expense?
- Edgewise Therapeutics, Inc. (EWTX) reported business segments — allocated share based compensation expense of $8.72M in Q1 2026.
- How has Edgewise Therapeutics, Inc.'s business segments — allocated share based compensation expense changed year-over-year?
- Edgewise Therapeutics, Inc.'s business segments — allocated share based compensation expense decreased by 3.8% year-over-year, from $9.06M to $8.72M.
- What is the long-term trend for Edgewise Therapeutics, Inc.'s business segments — allocated share based compensation expense?
- Over 2 years (2023 to 2025), Edgewise Therapeutics, Inc.'s business segments — allocated share based compensation expense has grown at a 40.7% compound annual growth rate (CAGR), from $17.56M to $34.75M.
- What does business segments — allocated share based compensation expense mean?
- Reflects the non-cash expense recognized for equity-based awards granted to employees and directors. This metric is essential for understanding the true cost of talent acquisition and retention without the impact of cash outflows. It highlights the dilution risk and alignment of management incentives with long-term shareholder value.